MedTrace Logo

Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

NCT05535062 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the comfort of the NeuroStar® Advanced Therapy System regular prescribed TMS protocol versus a New Feature.

Conditions

Interventions

DEVICE

repetitive Transcranial Magnetic Stimulation

the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function

Sponsors & Collaborators

  • Neuronetics

    lead OTHER

Principal Investigators

  • Steve A Erickson, BS · Neuronetics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2023-09-27
Completion
2023-09-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05535062 on ClinicalTrials.gov